Phase HI clinical trials

Clinical Global Impressions. Although the ECDEU Assessment Manual for Psychopharmacology (Guy, 1976) provides a formal test for the Clinical Global Impression (CGI) Scale, numerous investigators have modified the three major questions as well as the scales used in order to fit this test to their own clinical trials. The three questions, which may be apphed in almost all Phase II and Phase HI clinical trials, are... 

Figure 9 Treatment of operable brain tumors with BCNU-loaded, p(CPP SA)-based wafers. (A) Schematic cross sections through a brain The tumor is illustrated as a black circle (he surrounding tissue is infiltrated by cancer cells. Upon tumor resection, up to eight drug-loaded wafers (cylindrical disks) are placed into the resection cavity to minimize the risk of local tumor recurrence. (B) Overall survival of 222 patients with recurrent brain tumors (phase HI clinical trial, after adjustment for prognostic factors). (C) Overall survival of 240 patients with newly diagnosed brain tumors (phase HI clinical trial, including results from (he long-term follow-up). Abbreviation ITT, intent-to-treat Source From Refs. 58 and 63 (B and C).

Fattom A I, Horwith G, Fuller S (2004). Development of StaphVAX(TM), a polysaccharide conjugate vaccine against S. aureus infection From the lab bench to phase HI clinical trials. Vaccine. 22 880-887. 

Comparing a new medication with the standard treatment procedures is the purpose of a Phase HI clinical trial. 

Table 6.2 Duration of repeated-dose toxicity studies to support Phase HI clinical trials in the EU, and product marketing in all jurisdictions"...

Jackson Rosenbaum SE, Kerr BM, Pitiiavala YK, Yuen G, Dudley MN. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase HI clinical trial. Antimicrob Agents Chemother (2000) 44,1832-7. 

Antiviral agent and immu-nomodulator. Potentially useful in the treatment of chronic fatigue syndrome Synth, mismatched, double stranded RNA. Phase HI clinical trials (USA 1998)... 

It should be emphasized that NCT is still in the research phase with no Phase HI clinical trials having yet been performed. In addition, it has been concluded that the results of 320 patients treated in BNCT studies have not demonstrated any significant benefit for these patients. 

Freilich D, Pearce LB, Pitman A, Greenburg G, Berzins M, Bebris L, Ahlers S, McCarron R. HBOC-201 vaso-activity in a phase HI clinical trial in orthopedic surgery subjects—extrapolation of potential risk for acute trauma trials. J Trauma 2009 66(2) 365-76. 

Since API stability data are needed to support the three clinical phases, the selection of batches at each phase reflects the synthetic scheme and batch size used at that stage of development. In phase I studies, the batches used in the toxicological and clinical trials should be monitored. As the synthetic scheme and batch size evolve, batches made by the new process should be selected for stability testing and monitored for the duration of the phase II clinical trials. Knowledge about the API gathered in phases I and II should form the basis for the stability protocol for the API manufactured by the final synthetic process that will be used to support the phase HI clinical trials and the primary registration stability studies. 

Another oral prodrag of Huorouracil, Atofluding (36) is a diacyl derivative of 1. Atofluding has reached Phase HI clinical trials in China [39]. The activation of 36 includes its fast non-enzymatic hydrolysis to 3-o-toluyl-5-Fluorouracil (44) following oral administration 44 is then slowly metabolized to 1 (Scheme 6) [40]. Since the acetyl group of Atofluding is not stable and prone to decompose, impairing quality control for the preparation, a possibility of direct application of 44 was also considered [41]. 

Fourth, the chapters on Phase I clinical trials and pharmacoeconomic research have been written by experts in these fields. These are very rapidly-developing disciplines. The typical pharmaceutical physician has usually paid little attention to these aspects of clinical development, but it is our belief that these will dictate his/her clinical development plans to an ever-increasing degree in the future. Phase I studies can shorten overall clinical development time, and the pharmacoeconomic leveraging of (especially) Phase III and Phase IV studies (with preparatory Phase II work) are now essential in the modern competitive environment. 

Marketing may also benefit from Phase III clinical trials where compliance has been evaluated. It may become possible to estimate whether or not a patient will take his/her medicine regularly. Education of clinicians about the stages of treatment when the patient is most likely to either forget his/ her tablets or deliberately discontinue treatment (e.g. the weekend effect ) can permit relevant intervention and superior therapeutic results. 

A second lead HPMA copolymer-platinate (AP5346) has been identified with a similar Gly-Phe-Leu-Gly-aminomalonate side chain, but in this case terminating in a 1,2-diaminocyclohexyl (DACH) palatinate (Fig. 8). hi Phase 1 clinical trial, it was administered as intravenous infusion of 80-1280 mg Pt/m once a week in 28-day cycle to patients with a broad cross-section of tumour types. Out of the 12 evaluable patients, one demonstrated a partial response. Dose hmiting toxicity was neutropenia but also nausea, vomiting, asthenia, fatigue and diarrhoea were observed (as presented in October 2004 at the 16th... 

Choosing Laboratory Tests. There is no standardized series of laboratory parameters that are evaluated in all clinical trials, nor is there a single standard for drugs in Phases I, 11, or HI. There are, however, broad general guidelines for laboratory tests that reperformed at each stage of clinical development. 

The application of the principles of dose-response relations to Phase II and III clinical trials focuses on the practical aspect of determining which doses will be selected for these trials and which will be taken forward to registration (see below). Each subject in a clinical trial will have his or her own efficacy and safety dose-response curve for a given drug. The shape and position of these curves will be determined by individual subject characteristics - age, gender, genetically... 

---